Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cancer
    • Breakthrough: Amrita...

    Breakthrough: Amrita Scientists turn Bone biomineral into radio frequency agent for cheaper diagnosis of cancer

    Written by Medical Dialogues Bureau Published On 2018-01-29T22:56:59+05:30  |  Updated On 29 Jan 2018 10:56 PM IST
    Breakthrough: Amrita Scientists turn Bone biomineral into radio frequency agent for cheaper diagnosis of cancer

    In a project funded by the Dept. of Biotechnology, Govt. of India, Scientists of Centre for Nanosciences and Molecular Medicine at Kochi’s Amrita Institute of Medical Sciences have successfully turned nanoparticles of calcium phosphate, a biomineral naturally found in human bones into fully biodegradable radio frequency (RF) agents.These thereafter become imageable by MRI and CT scans. This breakthrough study has paved the path for safer, cheaper diagnosis and treatment of cancer.


    Dr Shanti Nair, Director, Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences, Kochi said: “The development of calcium phosphate nanoparticles with imageable properties for drug delivery applications is a major innovation in the quest to develop biodegradable contrast agents for imaging (diagnostic) purposes. Calcium phosphate is naturally found in human bones and is non-toxic and fully biodegradable. Now that its nanoparticles have been made imageable by MRI and CT scans, their accumulation in tumours can be verified and the MR contrast used for the image-guided surgical treatment of cancer.”


    Currently, the most common treatment for cancer involves radiation and use of gamma rays to kill cancer cells. However, this inflicts collateral damage – healthy cells also get destroyed along with cancer cells. Radiation treatment with Cyber-Knife is much more precise but very expensive. In this situation, the most easily accessible and cheapest cancer treatment available today uses radio frequency (RF) microwaves. But for this method to work, the RF agent should be non-toxic to human body and preferentially accumulated in the tumor. This is where the development of calcium phosphate nanoparticles as a biodegradable RF agent becomes significant.


    Dr. Manzoor Koyakutty, Professor, Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences, Kochi, and the project’s key principal investigator said: "The main advantage of calcium phosphate is that our body does not treat it as foreign material, leading to minimum toxicity and immune rejection compared to other engineered nanoparticles which are non-biodegradable. We have made this biomineral imageable using MRI and CT. It can be guided precisely to cancer tumours, which will enable their treatment under image guidance, using radio waves to heat up and destroy the cancerous cells. We are now conducting large animal studies, after which clinical trials will follow."


    The team of co-inventors has launched a new company which has already acquired the rights from Amrita Institute of Medical Sciences to bring the product to clinics. This spin-off venture is supported by the Biotechnology Innovation Grant of Department of Biotechnology, Govt. of India.


    The discovery of RF hyper-thermic property (heat generation under radio waves) of calcium phosphate was by chance. A team of researchers at Amrita Centre for Nanosciences and Molecular Medicine, including Dr Anusha Ashokan, Dr Vijay Harish and Dr GS Gowd, was doing experiments to optimize MRI imaging and RF properties of some calcium-containing materials. During experimentation, they accidentally found that the calcium compound was getting heated up when exposed to radio waves. This led to the optimization of calcium phosphate nanoparticles for RF applications. The scientists enhanced their hyper-thermic properties by doping them with iron nanoparticles having magnetic properties, which also helped in magnetic resonance imaging.


    Said Dr Vijay Harish, Physician Scientist, Dept. of Nuclear Medicine, Amrita Institute of Medical Sciences, Kochi: "Image-guided therapy using biodegradable material such as calcium phosphate is very attractive from the clinical perspective. It will allow doctors to treat cancer patients with precision.”


    BiomineralBiotechnology Innovation Grant of Department of BiotechnologybonesCalcium phosphatecancer cellscancer tumoursDept of BiotechnologyDept of Nuclear MedicineDirectorDr Anusha AshokanDr Manzoor KoyakuttyDr Shanti NairDr Vijay HarishDr Vijay Harish and Dr GS Gowdgamma raysMata AmritanandamayiMolecular MedicineNABL accreditednanoparticlesNanosciencesPhysician ScientistprofessorRadiationradio frequencyradio wavesResearchersRF hyperthermic property
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok